Surgify Secures €7 Million in Series A Funding to Expand Globally
Helsinki, Finland (May 27, 2025) – Surgify Medical, a Finnish medical technology company focused on enhancing the safety and precision of bone surgery with its Surgify Halo™ technology, has successfully raised seven million euros in a Series A funding round.
The investment will enable the company to advance its goal of becoming a leading provider in the multi-billion euro bone surgery technology market. Building on a successful launch in Sweden and the Nordic region, Surgify plans to expand its operations in Sweden, the EU, and the US, where leading clinics have already begun using the technology.
In Sweden, the technology has already been implemented at the University Hospital in Örebro. Evaluations are soon to commence at Sahlgrenska University Hospital in Gothenburg and Akademiska Sjukhuset in Uppsala. The company will also soon begin a clinical study with Capio Spine Center Stockholm to compare Surgify Halo with conventional bone drills.
The Series A funding was led by ZEISS Ventures, the venture capital arm of Carl Zeiss Group, with participation from the European Innovation Council Fund (EIC Fund). Surgify’s existing investors, including Swedish Lednil AB, also participated in the funding. Previous Swedish investors in the company and its technology include Andreas Bunge.
Traditional surgical bone drills rotate at tens of thousands of revolutions per minute and can be dangerous if they come into contact with critical soft tissue. In the worst-case scenario, such soft tissue damage can lead to serious complications for the patient. Soft tissue injuries pose a significant risk during cranial and spinal surgery requiring bone removal, and occur relatively frequently, resulting in more than 4 billion euros in complication-related costs each year globally.
Surgify Halo drills bone as effectively as current surgical bone drills while significantly reducing the risk of damage to sensitive tissues such as the spinal cord membrane, meninges, or blood vessels and nerves, thanks to its built-in safety mechanism. The technology is approved for use in the EU and the USA. Surgify Halo is designed to be easy to use and integrate seamlessly into existing surgical workflows.
“ZEISS has unparalleled experience in surgical technology and a global network, while the EIC’s continued support and previous grant funding underscore the European innovation ecosystem’s confidence in our solution,” says Tom Rönnlund, Global Chief Commercial Officer for Surgify Medical. “With this funding, we are well-positioned to bring our unique technology to more surgeons and patients in Sweden and internationally.”
“Surgify’s technology is a major breakthrough in today’s evolving healthcare landscape. With over a thousand completed surgeries, Surgify Halo has already established itself as a safe and effective solution to a common clinical complication. The company’s goal is to contribute to increased patient safety, save healthcare costs, and has already achieved groundbreaking results in robotic surgery applications in its product development program,” says Alan Raffensperger, Chairman of the Board for Surgify Medical.
“We are excited to partner with Surgify in their mission to establish a new benchmark for surgical safety. Surgify’s Halo drill offers exceptional stability and control while maintaining efficiency in bone removal, while protecting sensitive soft tissues. This makes the use of Surgify Halo an obvious choice for surgeons,” explains Dr. Boris Hofmann, Head of ZEISS Ventures. “We are eager to support the team as they expand their technology on a global scale.”
More Information:
- Mediakit with images
Tom Rönnlund
Chief Commercial Officer
tom.ronnlund@surgify.com
About Surgify Medical
Surgify Medical, based in Espoo, Finland, is dedicated to revolutionizing bone surgery by making it safer, faster, and more precise. The company’s flagship product, Surgify Halo™, is designed to differentiate between hard and soft tissues, significantly reducing the risk of serious surgical complications and streamlining procedures.
The benefits of Surgify Halo™ extend beyond the core market of head, neck, and spine surgery. Surgify’s technology also has the potential to revolutionize the growing field of robotic surgery by enabling reliable automated bone resection.
In 2024, Surgify Halo™ was awarded the prestigious Red Dot Award: Innovative Product 2024, receiving international recognition for its exceptional design, the use of advanced materials, and its groundbreaking approach to surgical innovation.
To date, Surgify Medical has raised 14 million euros in total funding and has offices in Finland, Sweden, Denmark, and the USA.
For more information, visit www.surgifymedical.com.
About ZEISS
ZEISS is an internationally leading technology enterprise operating in the fields of optics and optoelectronics. In the previous fiscal year, the ZEISS Group generated annual revenue totaling approximately 11 billion euros in its four segments Semiconductor Manufacturing Technology, Industrial Quality & Research, Medical Technology and Consumer Markets (30 September 2024).
For its customers, ZEISS develops, produces and distributes highly innovative solutions for industrial metrology and quality assurance, microscopy solutions for the life sciences and materials research as well as medical technology solutions for diagnostics and treatment in ophthalmology and microsurgery. The name ZEISS is also synonymous with the world’s leading lithography optics, which are used by the chip industry to manufacture semiconductor components. There is global demand for trendsetting ZEISS brand products such as eyeglass lenses, camera lenses and binoculars.
More information at www.zeiss.com
About the European Innovation Council Fund (EIC Fund)
The European Innovation Council Fund from the European Commission provides equity investments for breakthrough innovations across the EU. The EIC Fund serves as a catalyst for private investment and supports high-potential companies bringing transformative technologies to market.
Read more at: eic.ec.europa.eu.
Enjoyed this post by Thibault Helle? Subscribe for more insights and updates straight from the source.
